A Szentágothai János Kutatóközpont a PTE korszerű, nemzetközi tudományszervezési és menedzsment normák szerint kialakított új intézménye, amely az élettudományi, élettelen természettudományi, valamint környezettudományi oktatás...
The most significant research topic within this research group is heart failure, encompassing both left and right-sided conditions. Despite the expansion of therapeutic options over recent decades, heart failure remains a disease with a poor prognosis. Investigations are also being conducted into therapeutic approaches to other pathologies that result in heart failure, including myocardial infarction, hypertension, pulmonary arterial hypertension, and atrial fibrillation. The objective of these studies is to elucidate the role of specific signaling factors and mitochondrial quality control processes in the pathogenesis and progression of these diseases. Furthermore, new avenues for therapeutic intervention are explored. The methodological profile of these studies encompasses a range of approaches, from cell culture studies to isolated cardiac perfusion (e.g., ischemia-reperfusion, cold ischemia) and chronic animal models. Moreover, clinical trials were conducted on humans with stable coronary heart disease, systolic heart failure, and oncological diseases, with a particular emphasis on the cardiological effects of chemotherapeutics. Furthermore, the Animal Imaging Core Facility includes small animal echocardiography equipment.
Resveratrol and beyond: The effect of natural polyphenols on the cardiovascular system: A Narrative Review. Roland Gal, Robert Halmosi, Ferenc Jr. Gallyas, M. Tschida, P. Mutirangura, K. Tóth, T. Alexy, L. Czopf, (2023) Biomedicines 11: 2888. DOI: 10.3390/biomedicines11112888
The effect of resveratrol on the cardiovascular system from molecular mechanisms to clinical results. Roland Gal, Laszlo Deres, Kalman Toth, Robert Halmosi, Tamas Habon. Int J Mol Sci. 2021 Sep 21;22(18):10152. DOI: 10.3390/ijms221810152
Modulation of mitochondrial quality control processes by BGP-15 in oxidative stress scenarios: from cell culture to heart failure. Orsolya Horvath, Katalin Ordog, Kitti Bruszt, Nikoletta Kalman, Dominika Kovacs, Balazs Radnai, Ferenc Gallyas, Kalman Toth, Robert Halmosi, Laszlo Deres. Oxid Med Cell Longev. 2021 Feb 27;2021:6643871. DOI: 10.1155/2021/6643871
BGP-15 protects against heart failure by enhanced mitochondrial biogenesis and decreased fibrotic remodelling in spontaneously hypertensive rats. Orsolya Horvath, Katalin Ordog, Kitti Bruszt, Laszlo Deres, Ferenc Gallyas, Balazs Sumegi, Kalman Toth, Robert Halmosi. Oxid Med Cell Longev. 2021 Jan 30;2021:1250858. DOI: 10.1155/2021/1250858
Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes. Katalin Ordog, Orsolya Horvath, Krisztian Eros, Kitti Bruszt, Szilard Toth, Dominika Kovacs, Nikoletta Kalman, Balazs Radnai, Laszlo Deres, Ferenc Gallyas Jr, Kalman Toth, Robert Halmosi. Life Sci. 2021 Mar 1;268:118936. DOI: 10.1016/j.lfs.2020.118936
Protective effects of the novel amine-oxidase inhibitor multi-target drug SZV 1287 on streptozotocin-induced beta cell damage and diabetic complications in rats. Valéria Tékus, Ádám István Horváth, Kata Csekő, Krisztina Szabadfi, Andrea Kovács-Valasek, Bese Dányádi, László Deres, Róbert Halmosi, Éva Sághy, Zoltán V Varga, Ernest Adeghate, Tamás Kőszegi, Péter Mátyus, Róbert Gábriel, Péter Ferdinandy, Erika Pintér, Zsuzsanna Helyes. Biomed Pharmacother. 2021 Feb;134:111105. DOI: 10.1016/j.biopha.2020.111105
Resveratrol improves heart function by moderating inflammatory processes in patients with systolic heart failure. Roland Gal, Laszlo Deres, Orsolya Horvath, Krisztian Eros, Barbara Sandor, Peter Urban, Szilvia Soos, Zsolt Marton, Balazs Sumegi, Kalman Toth, Tamas Habon, Robert Halmosi. Antioxidants (Basel). 2020 Nov 11;9(11):1108. DOI: 10.3390/antiox9111108
Hemorheological alterations in patients with heart failure with reduced ejection fraction treated by resveratrol. Roland Gal, Dora Praksch, Peter Kenyeres, Miklos Rabai, Kalman Toth, Robert Halmosi, Tamas Habon. Cardiovasc Ther. 2020 Jun 30;2020:7262474. DOI: 10.1155/2020/7262474 .eCollection 2020.
The effects of bradykinin B1 receptor antagonism on the myocardial and vascular consequences of hypertension in SHR rats. Laszlo Deres, Krisztian Eros, Orsolya Horvath, Noemi Bencze, Csongor Cseko, Sandor Farkas, Tamas Habon, Kalman Toth, Robert Halmosi. Front Physiol. 2019 May 21;10:624. DOI: 10.3389/fphys.2019.00624
Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure. Adam Riba, Laszlo Deres, Krisztian Eros, Aliz Szabo, Klara Magyar, Balazs Sumegi, Kalman Toth, Robert Halmosi, Eszter Szabados. PLoS One. 2017 Apr 6;12(4):e0175195. DOI: 10.1371/journal.pone.0175195
Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats. Krisztian Eros, Klara Magyar, Laszlo Deres, Arpad Skazel, Adam Riba, Zoltan Vamos, Tamas Kalai, Ferenc Gallyas Jr, Balazs Sumegi, Kalman Toth, Robert Halmosi. PLoS One. 2017 Mar 24;12(3):e0174401. DOI: 10.1371/journal.pone.0174401
Cardioprotective effect of resveratrol in a postinfarction heart failure model. Adam Riba, Laszlo Deres, Balazs Sumegi, Kalman Toth, Eszter Szabados, Robert Halmosi. Oxid Med Cell Longev. 2017;2017:6819281. DOI: 10.1155/2017/6819281
PARP inhibition and postinfarction myocardial remodeling. Robert Halmosi, Laszlo Deres, Roland Gal, Krisztian Eros, Balazs Sumegi, Kalman Toth. Int J Cardiol. 2016 Aug;217 Suppl:S52-9. DOI: 10.1016/j.ijcard.2016.06.223
